# Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

> **NCT07446270** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Treatment for Advanced Colorectal Cancer
- Treatment for Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Colorectal cancer: Tunlametinib + cetuximab β
- **DRUG:** Pancreatic cancer: Tunlametinib + cetuximab β
- **DRUG:** Pancreatic cancer: Tunlametinib +Nimotuzumab

## Key facts

- **NCT ID:** NCT07446270
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2027-10-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07446270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07446270, "Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07446270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*